Serial

The goal of microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) is to be the first and the main publishing option for academic and industrial scientists, pathologists, clinicians, and other health care providers carrying out research on and/or interested in the development, implementation and application of microRNA-based diagnostic and therapeutic tools for management and treatment of human disease.

As methodological, experimental and intellectual challenges and solutions for microRNA-based diagnostic and therapeutic applications are likely to present both commonalities across disciplines and also peculiarities in specific diseases, miRNA Dx/Rx serves as a central portal to integrate the most up-to-date and relevant data on microRNA diagnostic and therapeutic studies and to disseminate this knowledge in a accessible manner to the research community at large.

In this initial period, microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) plans to attract well-established authors who are salient figures on the microRNA field and also authors with groundbreaking studies in any area of microRNA diagnostics and/or therapeutics. miRNA Dx/Rx will offer fast, constructive and comprehensive peer-review for a professional and satisfactory experience for submitting authors. The journal relevance and visibility will be based on the quality of the accepted publications and enhanced by active participation in and knowledge dissemination to the research community by its Editorial Advisory Board, who is constituted by prominent scholars and investigators internationally recognized as leaders in key areas of microRNA diagnostics and therapeutics.

After a decade of the discovery of this regulatory class of short non-coding RNA genes, microRNAs have brought about conceptual innovations and technological advances to virtually all fields of biological and biomedical sciences. In this relatively short period of time, thanks to intense, competent and competitive investigations, we have witnessed how basic research findings on specific microRNAs have already reached patients as phase II clinical trials. Collectively, these investigations have provided a solid foundation for the utilization of microRNA-based strategies in management and treatment of human disease.

Recognizing the extraordinary potential and dimension of this rapidly expanding field, microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) publishes original research and reviews on development, implementation and clinical application of microRNA-based diagnostic and therapeutic tools. miRNA Dx/Rx covers various areas of human disease, including cardiovascular and metabolic diseases, neurodegenerative conditions, and cancer. miRNA Dx/Rx focuses on diagnostic applications in clinical specimens and demonstration of therapeutic validity of microRNA-based approaches in animal models and advances to clinical implementation in clinical trials. 

• Journal Editor: Lorenzo F. Sempere, Dartmouth Medical School, USA

• Editors

Journal Editor

Lorenzo F. Sempere

lsempere@versita.com

Editorial Office

Versita Ltd.

ul. Solipska 14a/1

02-482 Warsaw, Poland

Phone: +48 22 701 50 15